After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

Apr 1, 2025
1 min read

He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.

https://vimeo.com/1071638927?share=copy

Recent Posts

See All

Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases

Cloverleaf Bio, a spinout out of Yale, announced $33M in seed financing today that will help it advance its work on a tRNA platform in oncology

Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight